Table 2 Discrimination of recrudescent from new infection episodes from cases in the drug efficacy trial in the Tehama region, Yemen based on msp1, msp2 and glurp genotyping
Case | Msp1 | Msp2 | Glurp | Outcome | |||
|---|---|---|---|---|---|---|---|
K1 | MAD20 | RO33 | FC27 | IC | |||
Case 1 | Â | Â | Â | Â | Â | Â | Â |
Day–0 | 180 | – | – | 300 | – | 1000 | RECRUDESCENCE |
Day–21 | 180 | – | – | 300 | – | 1000 | |
Case 2* | Â | Â | Â | Â | Â | Â | Â |
Day–0 | – | – | 150 | 450 | – | 900 | NEW INFECTION |
Day–21 | 200 | – | – | – | 500 | 1000 | |
Case 3 | Â | Â | Â | Â | Â | Â | Â |
Day–0 | 180 | – | – | – | 500 | 1000 | RECRUDESCENCE |
Day–28 | 180 | – | – | – | 500 | 1000 | |
Case 4 | Â | Â | Â | Â | Â | Â | Â |
Day–0 | 180 | – | 150 | 300 | 600 | 900 | RECRUDESCENCE |
Day–14 | 180 | – | 150 | 300 | 600 | 900 | |
Case 5* | Â | Â | Â | Â | Â | Â | Â |
Day–0 | 200 | – | – | 350 | – | 900 | NEW INFECTION |
Day–28 | – | 230 | – | 280 | – | 900 | |